If you’re looking at treatment options for a certain kind of lung cancer, your doctor might suggest Tabrecta (capmatinib). Learning about the possible side effects can help you know what to ...

Tabrecta (capmatinib) has potential interactions with other medications and some supplements. These interactions could affect how well the drug works or cause harmful effects. Tabrecta is used in ...

Novartis has exclusive worldwide development and commercialization rights to Tabrecta The approval of Tabrecta is based on results from the pivotal GEOMETRY mono-1 study. In the METex14 population ...

Tabrecta is the first and only therapy approved by the FDA to specifically target metastatic non-small cell lung cancer (NSCLC) with a mutation that leads to MET exon 14 skipping (METex14 ...

EAST HANOVER, N.J., May 6, 2020 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) approved Tabrecta ™ (capmatinib, formerly INC280), an oral MET inhibitor ...

Tabrecta (capmatinib) will treat patients with metastatic non-small cell lung cancer that has a mutation leading to MET exon 14 skipping. The drug is the first targeted option for patients with lung ...

Incyte, a global biopharmaceutical company, announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved Tabrecta (capmatinib) for MET exon 14 skipping (METex14) ...

The agency Wednesday approved Tabrecta (capmatinib) for metastatic non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping mutations, regardless of whether they’ve tried other ...

“The positive CHMP opinion for Tabrecta brings an option to patients for a treatment specific to their tumor. If approved by the European Commission, new targeted therapies like Tabrecta ...

FDA SAYS TABRECTA APPROVED FOR LUNG CANCER PATIENTS WHOSE TUMORS HAVE MUTATION LEADING TO MET EXON 14 SKIPPING AS DETECTED BY FDA-APPROVED TEST * FDA SAYS TABRECTA TABLETS APPROVED UNDER ...

Competition from other MET inhibitors like TABRECTA (capmatinib) exists, but TEPMETKO's once-daily dosing and efficacy profile offer differentiation. TEPMETKO is a kinase inhibitor prescribed for ...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved Tabrecta™ (capmatinib) for MET exon 14 skipping ...